Who is sponsoring NCT04652817?

NCT04652817 is sponsored by Mesoestetic Pharma Group S.L..

What drugs are being tested in NCT04652817?

Interventions in NCT04652817: MMI-22-04-2019.

What condition does NCT04652817 study?

NCT04652817 studies Labia Majora Atrophy and Hypotrophy.

Is NCT04652817 still recruiting?

NCT04652817 is currently completed. Last updated 3 December 2020.

Last reviewed 2020-12-03 · How we verify

NCT04652817

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of the Efficacy and Safety of the Dermal Filler for Augmentation of Labia Majora.

Completed NA Last updated 3 December 2020

What this trial tests

NA trial testing MMI-22-04-2019 in Labia Majora Atrophy and Hypotrophy in 35 participants. Completed in 26 August 2020.

Timeline

11 November 2019

Primary endpoint
12 July 2020

26 August 2020

Quick facts

Lead sponsor	Mesoestetic Pharma Group S.L.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	35
Start date	11 November 2019
Primary completion	12 July 2020
Estimated completion	26 August 2020
Sites	1 location across Bulgaria

Drugs / interventions tested

MMI-22-04-2019

Conditions studied

Labia Majora Atrophy and Hypotrophy — all drugs for Labia Majora Atrophy and Hypotrophy →

Sponsor

Mesoestetic Pharma Group S.L.

Who can join

18 and older, female only, with Labia Majora Atrophy and Hypotrophy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is an open-label uncontrolled single-center study for the evaluation of the Performance characteristics (efficacy and safety) of the dermal filler "MMI-22-04-2019" on the female genital area for the aesthetic, medicinal, functional and reconstructive indications.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Mesoestetic Pharma Group S.L. trials

Trials by the same sponsor.

NCT06477432 — Evaluation of the Safety and Performance Characteristics of Mesofiller Mesotox for the Correction of Wrinkles and Rehydr · NA · completed
NCT06486740 — Evaluation of the Safety and Performance Characteristics of Mesofiller Aox for the Correction of Mild and Moderate Facia · NA · completed
NCT05450380 — Clinical Investigation to Assess Safety and Performance of Dermal Filler of Hyaluronic Acid · NA · completed
NCT06482723 — Efficacy and Performance Evaluation of mGlobal L+AS 20 mg/ml Hyaluronic Acid, for the Correction of Light to Moderate Wr · NA · completed
NCT06451822 — Efficacy and Performance Evaluation of mIntense L+AS 25 mg/ml Hyaluronic Acid for the Correction of Moderate to Deep Wri · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04652817 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mesoestetic Pharma Group S.L.
Last refreshed: 3 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04652817.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing